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Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease of the 
central nervous system. The existence of autoantibody targeting aquaporin-4 (AQP4-Ab) 
indicates the involvement of humoral immunity in the pathogenesis of this disease. 
Rituximab (RTX), a monoclonal antibody against CD20, has been used to treat NMOSD 
by depleting circulating B  cells and overall satisfactory outcome has been achieved. 
Although T follicular helper cells have been proved to regulate B  cell activation and 
antibody production, the role of these cells in NMOSD and the impact of RTX treatment 
on these cells remain less understood. In this study, we found that frequencies of circu-
lating T follicular helper (cTfh) cells and B cells together with the related cytokines, IL-21 
and IL-6, were closely correlated with disease activity of NMOSD. Furthermore, B cell 
depletion with RTX treatment inhibited the expansion of cTfh cells, and these effects 
were achieved through eliminating IL-6-producing B cells and blocking the direct contact 
between cTfh cells and B cells. These findings imply the complicated cross talk between 
cTfh cells and B cells and may provide a novel therapeutic target for NMOSD.
Keywords: neuromyelitis optica spectrum disorder, circulating T follicular helper cells, rituximab, B  cells, 
interleukin-6
inTrODUcTiOn
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory demyelinating disease of 
the central nervous system (CNS) characterized by recurrent attacks of optic neuritis and transverse 
myelitis (1). In the past decades, NMOSD was believed to be a variant of multiple sclerosis (MS) 
based on the overlapping clinical and magnetic resonance imaging phenotypes. The identification 
of an autoantibody targeting aquaporin-4 (AQP4-Ab) has differentiated NMOSD from MS as an 
independent disease entity (2). AQP4-Ab is positive in more than half of patients with NMOSD, 
and its pathogenic role has been well demonstrated (3–5). Other antibodies against myelin antigens 
have also been reported in NMOSD, such as anti-MOG (6) and anti-MBP (7). Although the concrete 
role of these autoantibodies has not been clearly identified, recent evidence strongly suggested that 
humoral immunity would contribute to the pathology of NMOSD (8).
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T follicular helper (Tfh) cells, as a newly defined CD4+ T cell 
subset, are critical for B cell activation and differentiation (9, 10). 
Tfh cells constitutively express the chemokine receptor CXCR5, 
which allows them to migrate into germinal center (GC) (11) 
and provide costimulation signals, such as CD40L and IL-21, to 
B cells (12). Recently, circulating Tfh (cTfh) cells were identified 
to be the peripheral subsets of their GC counterparts (13). And 
an increased frequency of cTfh cells was observed in multiple 
antibody-mediated diseases (14–17).
Rituximab (RTX), which depletes circulating CD20+ B  cells, 
has emerged as the first-line immunosuppressant for treating 
NMOSD, though the precise mechanism still remains uncovered 
(18). In patients with MS, RTX treatment resulted in a significant 
decline of CNS-infiltrated T cells, which suggested this agent may 
also modulate T cell immune response besides depleting B cells 
(19). However in NMOSD, whether RTX exerts its therapeutic 
potential by regulating T cells, especially cTfh cells, still remains 
unclear.
In this study, we found that frequencies of cTfh cells and 
circulating B  cells together with the related molecules were 
closely associated with the disease activity of NMOSD. Next, we 
firstly demonstrated that B cell depletion with RTX reduced the 
frequency of cTfh cells through ablation of IL-6 signaling and 
blockade of direct B–cTfh cell contact. The results strongly sug-
gest the existence of B–cTfh cell interaction in NMOSD, which 
might provide a possible therapeutic target for this disease.
PaTienTs anD MeThODs
study Population
We enrolled patients with NMOSD from June 2015 to March 2016 
who fulfilled the 2015 revised NMOSD diagnostic criteria (20) in 
our department. Qualitative serum AQP4 antibody (AQP4-Ab) 
assay was done by cell-based indirect immunofluorescence 
[EUROIMMUN Medical Diagnostics (China) Co., Ltd.]. Patients 
with new neurologic symptoms and signs or deterioration of 
residual disability lasting for at least 24  h with new lesions on 
MRI were determined as relapse. Patients with a stable clinical 
status for at least 30 days since the last relapse were considered as 
remission and enrolled in this study. Meanwhile, gender- and age-
matched healthy volunteers were included as controls (healthy 
controls). The study was approved by the Tangdu Hospital Ethical 
Review Board of Fourth Military Medical University, and written 
informed consent was obtained from all the subjects.
sampling and Treatment
Blood samples were drawn from all the patients and HCs to col-
lect peripheral blood mononuclear cells (PBMCs) and plasma 
for detecting cell frequencies and cytokine concentrations, 
respectively. Rituximab (RTX) treatment was carried out in 
the patients based on clinical status and patient’s preference. 
Intravenous infusion of RTX at a fixed dose of 100 mg was per-
formed once weekly for three consecutive weeks, as previously 
described (21). Blood samples were collected again 1  month 
after RTX treatment. Meanwhile, plasma AQP4-Ab levels were 
measured, respectively, before and 1 month after RTX treatment 
in seropositive patients.
Flow cytometry
Peripheral blood mononuclear cells were isolated by density 
gradient centrifugation as previously reported (17). After washed 
twice with phosphate-buffered saline (PBS), PBMCs were incu-
bated with the following fluorochrome-conjugated monoclonal 
Abs: FITC-CD3, PerCP-Cy5.5-CD4, APC-CXCR5, PE-PD-1, 
PE-CD19, and relevant isotype controls (Biolegend, San Diego, 
CA, USA). After staining at 4°C for 30 min, PBMCs were washed 
twice with PBS containing 2% fetal bovine serum and then meas-
ured on a BD FACS Calibur instrument. cTfh cells were defined as 
CD3+CD4+CXCR5+PD-1+. Data were analyzed using the FlowJo 
7.6 software.
Detection of cytokines and aQP4-ab
Plasma levels of IL-21, IL-6, and IL-10 were measured with 
enzyme-linked immunosorbent assay (ELISA) (Biolegend for 
IL-21, and Dakewe for IL-6 and IL-10) according to the manufac-
turers’ instructions. For seropositive patients, plasma AQP4-Ab 
levels were also measured by ELISA (Cusabio, Wuhan, China).
cell sorting and culturing
Circulating CD4+ T cells and CD19+ B cells were isolated from 
PBMCs by using specific magnetic beads (Miltenyi Biotec, 
Bergisch, Germany). To explore the role of B  cells in mainte-
nance of cTfh cells and the underlying mechanisms, 2 × 105 of 
whole or B cell-depleted PBMCs were stimulated with 1 μg/ml 
plate-bounded anti-CD3 (Biolegend, San Diego, CA, USA) and 
1 μg/ml soluble anti-CD28 (Biolegend, San Diego, CA, USA) for 
72 h, in presence or absence of IL-6-neutralizing mAb (5 μg/ml; 
Biolegend, San Diego, CA, USA), in a 96-well flat-bottom plate. 
In the transwell culture system, 2 × 105 of B cell-depleted PBMCs 
were cultured and stimulated with anti-CD3/CD28 in the lower 
chamber and autologous B cells were seeded into the inner cham-
ber of 0.4 μm pore size (Merck Millipore, Billerica, MA, USA). 
Each coculture of cells was carried out in triplicate in the X-VIVO 
serum-free medium (Lonza, Basel, Switzerland) containing 1% 
penicillin/streptomycin (Sigma, St. Louis, MO, USA).
coculture of circulating cD4+ T cells and 
cD19+ B cells
To determine the potency of B cells in the maintenance of cTfh 
cells, 2 × 105 of CD4+ T cells were cocultured with autologous 
CD19+ B cells at different ratios (as indicated in Figure 5) for 72h 
in the presence of anti-CD3 (1 μg/ml) and anti-CD28 (1 μg/ml). 
Frequencies of cTfh cells were measured with the markers CD3, 
CD4, CXCR5, and PD-1 on a BD FACS Calibur instrument.
statistical analysis
Quantitative data are shown as means ±  SEM, and categorical 
data are presented as number with percentage. Statistical analysis 
was performed using the SPSS19.0 software. Demographic and 
clinical characteristics among the relapsing patients, remit-
ting patients, and HCs were compared with Fisher’s exact test 
(gender, AQP4-Ab positive) and ANOVA (age, duration of 
disease). Multiple comparisons among the different groups were 
carried out with ANOVA for normally distributed data and 
with Kruskal–Wallis H non-parametric test for non-normally 
TaBle 1 | Demographic and clinical characteristics of patients with 
nMOsD and hcs.
nMOsD hcs P value
relapse remission
n 15 16 18
Female, no. (%) 14 (93.3) 15 (93.8) 16 (88.9) 1.000
Age (years) 42.53 ± 3.16 47.19 ± 2.63 41.61 ± 2.81 0.343
Duration of disease 
(months)
3.19 ± 0.72 4.00 ± 0.79 NA 0.457
AQP4-Ab positive, 
no. (%)
11 (73.3) 13 (81.3) NA 0.685
Ab, antibody; AQP4, aquaporin-4; NMOSD, neuromyelitis optica spectrum disorders; 
HCs, healthy controls; NA, not applicable. Quantitative variables are presented as 
means ± SEM and categorical variables as number with percentages. Comparisons 
among the relapsing patients, remitting patients, and HCs were analyzed by ANOVA 
(age, duration of disease) and Fisher’s exact test (gender ratio, AQP4-Ab positive). A P 
value of <0.05 was assumed as statistically significant.
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distributed data. Comparison between pre- and post-RTX treat-
ment was performed with Wilcoxon matched-pairs signed-rank 
test. Pearson’s correlation test was used to measure the possible 
relationship between two variables of interest. A P value of less 
than 0.05 was considered as statistically significant.
resUlTs
Demographic and clinical characteristics 
of Patients with nMOsD and hcs
A total of 31 patients and 18 gender- and age-matched HCs 
were enrolled in this study, where NMOSD patients consisted 
of 15 relapsing and 16 remitting individuals. There were no 
difference found in the gender ratio and mean age among the 
relapsing patients, remitting patients, and HCs. A predominance 
of female was observed in both relapsing (93.3%) and remitting 
patients (93.8%) with a similar mean duration of disease (3.19 
vs 4.00 months). Serum AQP4-Ab was positive in 24/31 (77.4%) 
patients. There were 11/15 (73.3%) relapsing patients and 13/16 
(81.3%) remitting patients, respectively, positive for AQP4-Ab, 
with no significant intergroup difference seen (Table 1).
Frequencies of cTfh cells and B cells 
correlate with Disease activity of nMOsD
Flow cytometry results showed that the frequency of cTfh 
cells in the relapsing patients with NMOSD was significantly 
higher than those in the remitting patients and HCs, while 
no difference existed between the latter groups, suggesting a 
correlation with disease activity of NMOSD (Figures  1A,B). 
Moreover, there was a similar tendency on the change of 
frequency of peripheral B cells (Figures 1C,D). A positive cor-
relation was found between frequencies of cTfh cells and B cells 
among the patients with NMOSD (Figure  1E). Subsequently, 
we detected plasma AQP4-Ab levels in seropositive patients. 
No difference was found between the relapsing and remitting 
patients (Figure 1F). In addition, frequencies of both cTfh cells 
and B  cells had no correlations with plasma AQP4-Ab level 
(Figures 1G,H).
cytokines concentration in Patients  
with nMOsD and hcs
Given the fact that IL-21 and IL-6 are pivotal regulators of 
humoral immune response and play a crucial role in Tfh cell dif-
ferentiation, we evaluated the plasma levels of IL-21 and IL-6 by 
ELISA. There was a significant increase of plasma IL-21 and IL-6 
levels in the relapsing patients with NMOSD compared with the 
remitting patients and HCs (Figures 2A,B), which was consistent 
with the changes of cTfh cells and B cells. Meanwhile, plasma level 
of IL-10, an anti-inflammatory cytokine, was also detected and a 
significant increase was found in the relapsing patients. Although 
there was a tendency of higher IL-10 levels in plasma of remit-
ting patients than HCs, no significant difference was observed 
(Figure S1A in Supplementary Material). Correlation analysis 
revealed that plasma IL-21 level positively correlated with fre-
quencies of both cTfh cells and B cells (Figures 2C,D). The same 
phenomenon was observed for IL-6 (Figures 2F,G) but not for 
IL-10 (Figures S1B,C in Supplementary Material). In addition, no 
correlation was found between plasma levels of IL-21, IL-6, and 
IL-10, respectively, and plasma AQP4-Ab levels (Figures 2E,H; 
Figure S1D in Supplementary Material).
rTX Treatment reduced cTfh cells in 
Patients with nMOsD
RTX specifically depletes peripheral B cells and has been used as a 
first-line immunosuppressant for NMOSD. To further explore the 
possible effects of RTX on cTfh cells, eight seropositive patients 
with relapsing NMOSD enrolled in this study were treated with 
RTX in our center. The total lymphocyte counts in peripheral 
blood remained almost unchanged during RTX treatment 
(Figure 3A). All the patients responded well to RTX and circulat-
ing B cells were successfully depleted (Figures 3B,C; Table S1 in 
Supplementary Material). Furthermore, CD4+ T cells decreased 
after RTX treatment (Figure S2 in Supplementary Material). 
Notably, the frequency of cTfh cells was significantly declined 
with RTX treatment (Figure  3D). Furthermore, a decreased 
tendency of plasma AQP4-Ab level was observed after RTX treat-
ment but with no statistical significance (Figure 3E). Consistent 
with the change of cTfh cells, plasma levels of IL-21 and IL-6 
were obviously decreased with RTX treatment (Figures  3F,G), 
while no significant alteration of plasma IL-10 level was observed 
between pre- and post-RTX treatment (Figure 3H). Meanwhile, 
we did ex vivo experiments which showed that B cells depletion 
could significantly reduce the frequency of IL-21-secreting CD4+ 
T cells (i.e., Tfh cells). And the frequency of IL-17-secreting cells 
(i.e., Th17 cells) slightly decreased, whereas the frequency of the 
other CD4+ T cell subsets was almost unchanged. This finding 
suggested that Tfh cells may be more sensitive to B cells depletion 
(Figure S3 in Supplementary Material).
Both il-6 and Direct B/cTfh contact Were 
essential for the Maintenance of cTfh 
cells
It is known that Tfh cells promote B cell proliferation, activation, 
and differentiation. However, B-cell depletion with RTX in this 
study significantly decreased the frequency of cTfh cells. This 
FigUre 1 | Frequencies of circulating T follicular helper (cTfh) cells and circulating cD19+ B cells correlate with disease activity of neuromyelitis 
optica spectrum disorder (nMOsD). (a) Representative flow cytometry plots showing the frequency of CD4+CXCR5+PD-1+ cTfh cells in healthy controls (HCs), 
relapsing and remitting patients with NMOSD. (B) Comparison of the frequency of cTfh cells. (c) Representative flow cytometry plots gated on lymphocytes 
showing frequency of circulating CD19+ B cells. (D) Comparison of the frequency of circulating CD19+ B cells. (e) Correlation between frequencies of cTfh cells and 
circulating CD19+ B cells. (F) Comparison of plasma AQP4-Ab level between the relapsing and remitting seropositive patients with NMOSD. (g) Correlation between 
the frequency of cTfh cells and plasma AQP4-Ab level. (h) Correlation between the frequency of circulating CD19+ B cells and plasma AQP4-Ab level. Each symbol, 
including solid circle, square, and triangle, represents one subject’s result. Horizontal lines in panels (B,D,F) illustrate the mean frequencies or levels with SEM.  
P values are shown.
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suggested that B cells might contribute to the maintenance of cTfh 
cells reciprocally. To verify this hypothesis, PBMCs from patients 
with NMOSD were cultured ex vivo upon stimulation with anti-
CD3/CD28, in parallel, B  cell-depleted PBMCs were cultured 
to mimic RTX treatment. We observed a significantly reduced 
frequency of cTfh cells in B cell-depleted group (Figures 4A,C). 
To verify whether B  cells directly affect the frequency of cTfh 
cells, we cocultured CD4+ T cells with B cells in different ratios 
under anti-CD3/CD28 stimulation and found that cTfh cells were 
maintained by B cells in a ratio-dependent manner (Figure 5), 
which suggested the direct supporting function of B cells.
In addition to the rise of plasma IL-6 level in relapsing patients 
(Figure 2B) and its positive correlation with circulating B cells in 
NMOSD (Figure 2G), we further observed an elevated mRNA 
level of IL-6 in B cells from the relapsing patients (Figure S4 in 
Supplementary Material), suggesting that B cells might maintain 
cTfh population through secretion of IL-6. As expected, IL-6 
blockade indeed obviously reduced the frequency of cTfh cells 
in the culture system of PBMCs even though B  cells were not 
depleted (Figures 4A,C). Besides, lack of direct contact between 
B cells and cTfh cells in a transwell culture system also led to a sig-
nificant reduction of the frequency of cTfh cells (Figures 4A,C). 
Furthermore, all of the B-cell depletion, IL-6 blockade, and 
transwell experiments significantly reduced the protein level of 
CXCR5 and PD-1 on cTfh cells, as shown by the mean fluores-
cence intensity (MFI) in Figure 4B.
FigUre 2 | Plasma cytokine levels in healthy controls (hcs), the relapsing and remitting patients with neuromyelitis optica spectrum disorder 
(nMOsD). (a) Comparison of plasma IL-21 level. (B) Comparison of plasma IL-6 level. (c) Correlation between plasma IL-21 level and the frequency of circulating 
T follicular helper (cTfh) cells in all enrolled patients with NMOSD. (D) Correlation between plasma IL-21 level and the frequency of circulating CD19+ B cells in all 
enrolled patients with NMOSD. (e) Correlation between plasma IL-21 level and AQP4-Ab in seropositive patients with NMOSD. (F) Correlation between plasma IL-6 
level and the frequency of cTfh cells in all enrolled patients with NMOSD. (g) Correlation between plasma IL-6 level and the frequency of circulating CD19+ B cells in 
all enrolled patients with NMOSD. (h) Correlation between plasma level of IL-6 AQP4-Ab in seropositive patients with NMOSD. Each symbol represents one 
subject’s result. Horizontal lines in panel (c) illustrate the mean frequencies with SEM. P values are shown.
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DiscUssiOn
T follicular helper cells have been identified as the most potent 
regulator of humoral immunity. Given the location of Tfh cells 
in the GC of secondary lymphoid organs, it is extremely hard to 
be obtained from patients routinely. Morita and colleagues have 
demonstrated that circulating CD4+CXCR5+ T cells appeared to 
be the memory subset of GC Tfh pool and had the same capacity 
to regulate B cells (13), which facilitated researchers to explore 
the role of these cells in human diseases. IL-21 and IL-6 are two 
major cytokines in regulating GC response, including Tfh cell 
proliferation and differentiation, B cell activation, and antibody 
production (22). A lack of both IL-6 and IL-21 fails to induce Tfh 
cell-dependent immune response; moreover, activated Tfh cells 
can produce a considerable amount of IL-21 (22). In accordance 
with a previous report (23), herein, we found that the frequency 
of cTfh cells as well as plasma levels of IL-21 and IL-6 were signifi-
cantly upregulated in relapsing patients with NMOSD but not in 
remitting patients, compared with those in HCs. Both IL-21 and 
IL-6 were positively correlated with the frequency of cTfh cells. 
These results suggested that cTfh cells might be involved in the 
pathogenesis of NMOSD and the frequency of cTfh cells, together 
with plasma levels of IL-21 and IL-6, could be used as biomarkers 
for monitoring disease activity of NMOSD.
T follicular helper cells play the central role in helping B cells 
activation and differentiation, which is protective against infec-
tion. However, overactivity of Tfh response could manifest as 
many immune-related disorders, such as autoimmunity (24). The 
FigUre 3 | B-cell depletion with rTX decreases the frequency of circulating T follicular helper (cTfh) cells and plasma levels of il-21 and il-6.  
(a) Comparison of total lymphocyte counts between pre- and post-RTX treatment. (B) Comparison of the frequency of circulating CD19+ B cells. (c) Comparison of 
the frequency of CD19+CD27+ memory B cells. (D) Comparison of the frequency of cTfh cells. (e) Comparison of plasma AQP4-Ab level. (F) Comparison of plasma 
IL-21 level. (g) Comparison of plasma IL-6 level. (h) Comparison of plasma IL-10 level. Line represents the changes of the frequency of specific cells, plasma 
AQP4-Ab, and cytokine levels before and after RTX treatment. P values are shown.
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frequency of Tfh cells, together with the titer of autoantibodies, 
was found to elevate in many autoimmune disorders, both in ani-
mal models and human (14–17, 25–28). In this study, although no 
correlation between plasma AQP4-Ab level and disease activity of 
NMOSD was observed, the frequencies of circulating B cells and 
cTfh cells were synchronously upregulated in relapsing patients 
and positively correlated with each other. However, in our study, 
no correlation of AQP4-Ab titers with disease activity is observed, 
which is consistent with previous studies (29). This implies that 
cTfh cells might promote NMOSD by activating B cells to secrete 
cytokines other than producing antibodies, a hypothesis that 
needs further investigation.
B  cells might contribute to autoimmunity via multiple 
ways, including antigen presentation, cytokine secretion, and 
antibody production. Depleting B cells with RTX is an effective 
approach to treat autoimmune disease, though the underlying 
mechanisms still remain debatable. In this study, circulating 
B  cells were successfully depleted even by a reduced dose of 
RTX, which was consistent with a previous study (21). However, 
RTX treatment could only moderately reduce plasma level of 
AQP4-Ab, probably attributed to the fact that RTX removed 
CD20+ B  cells but spared CD20− antibody-producing plasma 
cells. Likewise, several studies reported that RTX treatment was 
effective for NMOSD (29) and other autoimmune diseases even 
in patients who showed no decline of autoantibody titers (30, 
31), or the benefit of RTX treatment usually preceded the drops 
of antibody levels (30). All the findings suggested that B cells 
could contribute to the pathology through mechanisms other 
than antibody production.
Interestingly, we found that CD4+ T cells declined after RTX 
treatment. Given the multiple effects of B cells on T cell function, 
we think that RTX treatment may indeed have a non-specific 
effect on the frequency of the entire CD4+ T  cells. Due to the 
fact that Tfh cells are the true activator of humoral immunity, 
our study focused on the impact of RTX treatment on cTfh cells 
and its related mechanism. We found that RTX treatment also 
significantly reduced the frequency of cTfh cells in patients with 
NMOSD. Other studies have also reported this phenomenon in 
some other autoimmune diseases (32, 33), but they did not elabo-
rate the concrete mechanisms involved. We then further tried 
to explore the potential mechanisms via which B cells regulate 
Tfh response. A candidate factor may be IL-6, since it has been 
proved to play a vital role in the differentiation of Tfh cells (34). 
A study showed that B cells could secret an abundance of IL-6 
and exhibited pathogenic effects in experimental autoimmune 
encephalomyelitis, an animal model for MS (35). Furthermore, 
circulating plasmablasts could induce the differentiation of Tfh 
cells via producing IL-6 in patients with rheumatoid arthritis, and 
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IL-6 blockade reduced the population of Tfh cells (36). Indeed, 
we observed a significant increase of plasma IL-6 level in patients 
with NMOSD and further demonstrated an elevated mRNA 
level of IL-6 in B cells, which suggested that B cells might be an 
important origin of IL-6. B cell depletion, both ex vivo and in vivo, 
decreased cTfh cells from patients with NMOSD, and this effect 
was achieved in a ratio-dependent manner ex vivo. Meanwhile, 
plasma IL-6 level was markedly decreased with RTX treatment 
in parallel with the change of frequency of B cells. Further study 
showed that IL-6 was required for the maintenance of cTfh cells 
by B cells, since blockade of IL-6 reduced the frequency of cTfh 
cells in the coculture system. Moreover, the intimate contact 
between B cells and cTfh cells was also essential for the survival 
of cTfh cells as proved by a transwell culture system. This contact-
dependent maintenance of Tfh cells by B cells in this disease could 
be achieved by the crosslink of ICOS–ICOSL (37), OX40–OX40L 
(38), and MHC-II–TCR (39, 40) on the surface of these cells. But 
the central molecule involved in the cell–cell contact in this disease 
still needs a further research. Previous studies have reported that 
IL-6 and these costimulatory molecules were able to stimulate the 
FigUre 4 | Both il-6 production and direct cell–cell contact are necessary for the maintenance of circulating T follicular helper (cTfh) cells by 
B cells. B cell-depleted and whole peripheral blood mononuclear cells (PBMCs) from patients with neuromyelitis optica spectrum disorder were cultured upon 
stimulation with anti-CD3/CD28 for 72 h (n = 4), then the frequency of cTfh cells in the coculture system was measured. (a) Representative flow cytometry plots 
showing the frequency of T follicular helper cells of indicated cultured conditions. (B) Mean fluorescence intensity (MFI) of CXCR5 (left) and PD-1 (right) of 
CD4+CXCR5+PD-1+ T cells in each group. (c) Comparison of the frequency of cTfh cells in panel (a). P values are shown.
FigUre 5 | reduced B cells attenuate the maintenance of T follicular helper (Tfh) cells in a ratio-dependent manner. Circulating CD19+ B cells were 
cultured with CD4+ T cells on different ratios of 1:1, 1:10, and 1:100 and stimulated with anti-CD3/CD28 for 72 h. Maintenance of Tfh cells by B cells was estimated 
by flow cytometry. (a) Representative flow cytometry plots showing the frequency of Tfh cells. (B) Cumulative data showing the frequency of Tfh cells (n = 4 for each 
group). A reduced ratio of B cells in the coculture system was accompanied by the gradually attenuated maintenance of Tfh cells. P values are shown. 
Representative data are from three independent experiments.
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